New advances in cancer therapy targeting TGF-β signaling pathways

作者：Minyue Shou, Hanyu Zhou, Ling Ma · 发表于：Molecular Therapy — Oncolytics · 年份：2023 · DOI：10.1016/j.omto.2023.100755 · 被引用次数：31 · 研究领域：Cancer Research and Treatments、Cancer Immunotherapy and Biomarkers、CAR-T cell therapy research

Secretion of transforming growth factor β (TGF-β) is a prominent feature of cancer development and a striking way to inhibit anti-tumor immunity. Elimination effects of TGF-β have far-reaching positive implications for future immunotherapy. In their article, Petersen et al. designed hemagglutinin (HA)-tagged decoy receptors comprised of the extracellular domain of TGF-βRII (TβRII-ecto) attached to glycosylphosphatidylinositol (GPI) anchors, which resulted in a profound inhibition of TGF-β-induced SMAD phosphorylation.